GlobeNewswire
EUDA Health Holdings Limited Announces Execution of Securities Purchase Agreement
📈
AI Sentiment
Highly Positive
8/10
as of 12-05-2025 4:00pm EST
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | KANSAS CITY |
| Market Cap: | 27.0M | IPO Year: | 2021 |
| Target Price: | $32.67 | AVG Volume (30 days): | 128.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.20 - $6.01 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
CING Breaking Stock News: Dive into CING Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
8/10
See how CING stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CING Cingulate Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.